A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER).
暂无分享,去创建一个
A. Grothey | A. Cercek | M. Fakih | T. Bekaii-Saab | D. Niedzwiecki | Christina Wu | K. Ng | J. Strickler | S. Peterson | F. Sanchez | Lorelei A. Bandel | Tyler Zemla